Jul. 13 at 2:51 PM
$SKYE GROK analyzes SKYE:
Potential Gains:
Short-Term (2025–2026): Positive CBEYOND data could drive SKYE’s stock to
$20–
$30 (100–200% gain), based on X optimism and biotech rally trends.
Long-Term (2028–2030): Approval and 1–3% market share could push SKYE to
$50–
$100/share (400–900% gain), assuming
$1–
$3B annual sales at 5x sales multiple (biotech norm).
Buyout Potential: Acquisition by big pharma (e.g., Pfizer, Amgen) could yield
$5–
$10B valuation, or
$150–
$300/share, given obesity deal precedents (Roche-Carmot).
Attainable Market Cap:
Current:
$280M (small-cap, high-risk).
2026 (Post-Phase 2):
$1–
$2B if CBEYOND succeeds, driven by clinical momentum and partnership speculation.
2030 (Post-Approval):
$5–
$15B with 1–3% market share, or
$50–
$150B if nimacimab becomes a best-in-class combo therapy
Rationale: Biotech valuations soar with approvals (e.g., Lilly’s
$800B market cap post-Zepbound)
